Press Releases BioMarin Pharmaceutical Inc.

Equities

BMRN

US09061G1013

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
82.13 ^USD	+1.51%		-10.79%	-14.82%

Apr. 29	BioMarin Pharmaceutical Investors Overfocused on Roctavian, Distracted From Enzyme Replacement Therapies, UBS Says	MT
Apr. 25	Scotiabank Adjusts Price Target on BioMarin Pharmaceutical to $85 From $83, Maintains Sector Perform Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioMarin: Q1 Earnings Snapshot	Apr. 24	AQ
BioMarin Reports Record Financial Results for the First Quarter 2024	Apr. 24	PR
BioMarin Pharmaceutical : IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE - Form 8-K	Apr. 23	PU
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET	Apr. 10	PR
New Data to be presented for BioMarin's VOXZOGO in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting	Mar. 13	AQ
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer	Mar. 07	PR
BioMarin Scheduled to Participate in March Investor Conferences	Mar. 04	AQ
BioMarin Scheduled to Participate in March Investor Conferences	Mar. 01	PR
BioMarin: Q4 Earnings Snapshot	Feb. 22	AQ
BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024	Feb. 22	PR
BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET	Feb. 08	PR
BioMarin to Present ROCTAVIAN Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders Congress	Feb. 07	AQ
BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress	Feb. 06	PR
BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT 1:30 pm ET, in San Francisco, CA	Jan. 04	AQ
BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA	Jan. 03	PR
BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN for Severe Hemophilia A in Germany	Nov. 29	AQ
BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany	Nov. 28	PR
BioMarin Announces Retirement of Jean-Jacques Bienaime, Appoints Alexander Hardy President and Chief Executive Officer	Nov. 02	AQ
BioMarin: Q3 Earnings Snapshot	Nov. 01	AQ
BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year	Nov. 01	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BioMarin Pharmaceutical Inc.

Equities

BMRN

US09061G1013

Press Releases

Filters